(Q33409030)

26 July 2017

Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome (English)

1 reference

26 July 2017

2

Moin A Saleem

1 reference

26 July 2017

1

Lindsay S Keir

1 reference

26 July 2017

11 July 2013

1 reference

26 July 2017

1 reference

26 July 2017

29

1 reference

26 July 2017

10

1 reference

26 July 2017

1895-1902

1 reference

https://scigraph.springernature.com/pub.10.1007/s00467-013-2561-1

26 July 2017

0 references

cites work

Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS).

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Thrombotic microangiopathy and associated renal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Microalbuminuria three years after recovery from Escherichia coli O157 hemolytic uremic syndrome due to municipal water contamination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Albuminuria and estimated GFR 5 years after Escherichia coli O157 hemolytic uremic syndrome: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Risk factors for poor renal prognosis in children with hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Renal and neurological involvement in typical Shiga toxin-associated HUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Treatment of typical (enteropathic) hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Clinical practice. Today's understanding of the haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Pathogenesis of thrombotic microangiopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Eculizumab for congenital atypical hemolytic-uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Complement genetics, deficiencies, and disease associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Molecular intercommunication between the complement and coagulation systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Thrombomodulin mutations in atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Complement activation on platelets: implications for vascular inflammation and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Platelet-associated complement factor H in healthy persons and patients with atypical HUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Decrease of thrombomodulin contributes to the procoagulant state of endothelium in hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Markers of endothelial cell activation and injury in childhood haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

aHUS caused by complement dysregulation: new therapies on the horizon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Eculizumab in severe Shiga-toxin-associated HUS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Treatment of typical hemolytic-uremic syndrome. Knowledge gained from analyses of the 2011 E. coli outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Microparticle generation and leucocyte death in Shiga toxin-mediated HUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Shiga toxin binds to activated platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Platelet activation in hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Shiga toxin 2 targets the murine renal collecting duct epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

VEGF inhibition and renal thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2)- and protein kinase C-alpha/epsilon (PKCalpha/epsilon)-dependent cytoprotective signaling pathway an

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Eculizumab for Atypical Hemolytic–Uremic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Complement cascade in systemic lupus erythematosus: analyses of the three activation pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2561-1

Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome

21 January 2018

1 reference

12 December 2020

The complement system in hemolytic-uremic syndrome in childhood

1 reference

12 December 2020

Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells

1 reference

12 December 2020

Long-term outcomes of Shiga toxin hemolytic uremic syndrome

1 reference

12 December 2020

Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells

1 reference

12 December 2020

Interaction between the coagulation and complement system

1 reference

12 December 2020

Breakdown products of C3 and factor B in hemolytic-uremic syndrome

1 reference

12 December 2020

Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies

1 reference

12 December 2020

10.1007/S00467-013-2561-1

Identifiers

DOI

1 reference

PubMed ID

23843163

Dimensions Publication ID

26 July 2017

0 references

1 reference

PubMed ID

23843163